Topic

President and CEO, The Corporate Citizenship Project

Articles

Rise in demand for sustainable practices forces industry to be more proactive.

Why Pharmaceutical Manufacturers Must Navigate Muddy Waters of ESG Requirements

Looking to the past reminds industry of great strides taken in clinical research for patients.

Remembering That TIME Magazine Issue; Celebrating Progress in Patient Engagement

Despite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.

Why Machine Learning's Potential in Pharma Relies on Its Transparency

How early stage can help set you up for big stage.

Seven Lessons I Learned Working at a Biotech Startup

Rohit Gupta is vice president of analytics strategy and transformation at 

Continued push for latest technology in biopharma will advance collection of patient data.

Web3 Promises to Unleash Health Data: What Does That Mean for Biopharma?

Obstacles in data exchange remain for industry.

Does the Oracle-Cerner deal represent a digital breakthrough in healthcare?

As big tech’s healthcare disruption efforts flag, biopharma can step up to empower patients and improve care, writes Rohit Gupta.

Biopharma Companies Must Go All-In on Patient Centricity

Niko Andre, MD, is Global Franchise Head, Hematology and Immuno Oncology at AstraZeneca.


He is responsible for building and advancing the global hematology and immuno oncology franchises including driving global commercial strategies, product launches and lifecycle management.

He is a medical oncologist by training and has first-hand experience treating and managing hematologic malignancies. He is passionate about translating scientific progress into clinically meaningful outcomes for patients living with serious disease and looking beyond the pill across the entire healthcare ecosystem to treat and support the patient wherever they are in their disease journey.

Prior to joining AstraZeneca, Niko spent nearly 15 years at the Roche Group having most recently served as Senior Vice President, Global Head Medical Affairs, Pharma. In this role, he was responsible for the creation, resourcing and implementation of a global medical strategy contributing to lifecycle entry decision, filing, launch, health technology assessment and commercialization for the entire pharma portfolio. This included compounds within oncology, hematology, neuroscience, rare diseases, immunology, infectious disease and ophthalmology.

AstraZeneca’s Niko Andre discusses the power of patient partnership in driving medical progress.

Redefining Care through Patient Partnership

Admirable Legacies

Jeremy (“Jerry”) V. Gross is the chief executive officer and co-founder at 

, a healthcare technology company. As CEO, Jerry is responsible for overseeing the vision, strategy, and growth of the company as well as its newly launched platform-as-a-service, VytalOS, which offers consumers frictionless prescription management and delivery. Jerry has 30+ years of experience leading development teams and leveraging emerging technologies to create disruptive innovation within biopharma, healthcare, and the financial technology industries.

Stay-at-home orders during the pandemic forced a shift in patient preferences—and the pharma industry has responded.

Opinion